Related Experiment Videos
Supravalvar aortic stenosis secondary to familial hypercholesterolaemia. Report of two cases
Insights
Familial hypercholesterolaemia can cause supravalvar aortic stenosis, a rare condition. Echocardiography aids diagnosis, and gemfibrozil showed promise in managing high cholesterol levels in one patient.
Area of Science:
- Cardiology
- Genetics
- Metabolic Disorders
Background:
- Familial hypercholesterolaemia (FH) is an inherited disorder causing extremely high cholesterol levels.
- Supravalvar aortic stenosis (SVAS) is a rare congenital narrowing of the aorta.
- FH type II A hyperlipoproteinaemia is a specific subtype characterized by elevated low-density lipoprotein (LDL) cholesterol.
Observation:
- Two cases of SVAS were identified in patients with FH type II A hyperlipoproteinaemia.
- Echocardiography was utilized to diagnose this uncommon association.
- One patient experienced a significant reduction in serum cholesterol following gemfibrozil treatment.
Findings:
- This report highlights the link between FH and SVAS, emphasizing its rarity.
- Echocardiography is a crucial diagnostic tool for identifying SVAS in the context of hyperlipoproteinaemia.
- Gemfibrozil demonstrated potential efficacy in managing hypercholesterolaemia associated with SVAS.
Implications:
- Increased awareness of the potential cardiovascular complications of FH is warranted.
- Echocardiography should be considered in the diagnostic workup of patients with FH presenting with suggestive symptoms.
- Further research into the management of hypercholesterolaemia in patients with FH-associated SVAS is needed.
Abstract:
Two cases of supravalvar aortic stenosis secondary to familial hypercholesterolaemia (type II A hyperlipoproteinaemia) are reported and the role of echocardiography in the diagnosis of this uncommon condition is discussed. The management of these patients is difficult and in one patient the serum cholesterol decreased substantially after treatment with gemfibrozil.